• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种 K-17 血清型特异性肺炎克雷伯菌噬菌体 JKP2,具有减少生物膜的潜力。

A K-17 serotype specific Klebsiella phage JKP2 with biofilm reduction potential.

机构信息

Institute of Microbiology and Molecular Genetics, University of the Punjab, Lahore, Pakistan; Department of Pathology, King Edward Medical University, Lahore, Pakistan.

Institute of Microbiology and Molecular Genetics, University of the Punjab, Lahore, Pakistan; Department of Microbiology, Hazara University, Mansehra, Pakistan.

出版信息

Virus Res. 2023 May;329:199107. doi: 10.1016/j.virusres.2023.199107. Epub 2023 Apr 2.

DOI:10.1016/j.virusres.2023.199107
PMID:36996938
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10194101/
Abstract

Klebsiella pneumoniae is an opportunistic pathogen responsible for nearly one-third of all Gram-negative infections. Increasing antibiotic resistance has pushed scientists to look for alternative therapeutics. Bacteriophages have emerged as one of the promising alternatives. In the current study, the Klebsiella phage JKP2 was isolated from a sewage sample and characterized against the K-17 serotype of K. pneumoniae. It produced bulls-eye-shaped clear plaques and has a latent period of 45 min with a burst size of 70 pfu/cell. It remained stable at tested pH (5 to 10) and temperatures (37 to 60 °C). Its optimum temperature for long-term storage is 4 °C and -80 °C. The JKP2 showed its infectivity against the K. pneumoniae K-17 serotype only. It controlled planktonic cells of K. pneumoniae 12 h post-incubation. At MOI-1, it efficiently eliminated 98% of 24 and 96% of 48-hour-old biofilm and 86% and 82% of mature biofilm of day 3 and 4, respectively. The JKP2 has an icosahedral capsid of 54 ± 0.5 nm with a short, non-contractile tail, measuring 12 ± 0.2 nm. It possesses a double-stranded DNA genome of 43.2 kbp with 54.1% GC content and encodes 54 proteins, including 29 with known functions and 25 with unknown functions. JKP2 was classified as Drulisvirus within the Autographiviridae family. It uses a T7-like direct terminal repeat strategy for genome packaging. JKP2 can be applied safely for therapeutic purposes as it does not encode an integrase or repressor genes, antibiotic resistance genes, bacterial virulence factors, and mycotoxins.

摘要

肺炎克雷伯菌是一种机会致病菌,可导致近三分之一的革兰氏阴性菌感染。不断增加的抗生素耐药性促使科学家寻找替代疗法。噬菌体已成为一种很有前途的替代品。在本研究中,从污水样本中分离出一株肺炎克雷伯菌噬菌体 JKP2,并针对肺炎克雷伯菌 K-17 血清型进行了鉴定。它产生牛眼状清晰噬菌斑,潜伏期为 45 分钟,爆发量为 70 个空斑形成单位/细胞。它在测试的 pH 值(5 至 10)和温度(37 至 60°C)下均保持稳定。其长期储存的最佳温度为 4°C 和-80°C。JKP2 仅对肺炎克雷伯菌 K-17 血清型表现出感染性。孵育 12 小时后,它可控制肺炎克雷伯菌浮游细胞。在 MOI-1 时,它能有效清除 24 小时和 48 小时老化生物膜的 98%和 96%,以及第 3 天和第 4 天成熟生物膜的 86%和 82%。JKP2 具有一个 54±0.5nm 的二十面体衣壳,带有一个短的、不可收缩的尾巴,长 12±0.2nm。它具有一个 43.2kbp 的双链 DNA 基因组,GC 含量为 54.1%,编码 54 种蛋白质,其中 29 种具有已知功能,25 种具有未知功能。JKP2 被归类为 Autographiviridae 科的 Drulisvirus。它使用类似于 T7 的直接末端重复策略进行基因组包装。由于 JKP2 不编码整合酶或抑制基因、抗生素耐药基因、细菌毒力因子和霉菌毒素,因此可以安全地应用于治疗目的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36dc/10194101/81399b1ac0a6/gr14.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36dc/10194101/6b1614ecb309/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36dc/10194101/7dea6aff2535/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36dc/10194101/451b0ded07fd/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36dc/10194101/b0b6712b1f48/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36dc/10194101/de8f3fa5fcb0/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36dc/10194101/8834e593628f/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36dc/10194101/9457893df886/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36dc/10194101/87a205fbd748/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36dc/10194101/83289270e7a3/gr9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36dc/10194101/53c15aec60e2/gr10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36dc/10194101/d7bf9de72049/gr11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36dc/10194101/cbe279405c00/gr12.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36dc/10194101/63ec05f76b52/gr13.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36dc/10194101/81399b1ac0a6/gr14.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36dc/10194101/6b1614ecb309/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36dc/10194101/7dea6aff2535/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36dc/10194101/451b0ded07fd/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36dc/10194101/b0b6712b1f48/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36dc/10194101/de8f3fa5fcb0/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36dc/10194101/8834e593628f/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36dc/10194101/9457893df886/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36dc/10194101/87a205fbd748/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36dc/10194101/83289270e7a3/gr9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36dc/10194101/53c15aec60e2/gr10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36dc/10194101/d7bf9de72049/gr11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36dc/10194101/cbe279405c00/gr12.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36dc/10194101/63ec05f76b52/gr13.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36dc/10194101/81399b1ac0a6/gr14.jpg

相似文献

1
A K-17 serotype specific Klebsiella phage JKP2 with biofilm reduction potential.一种 K-17 血清型特异性肺炎克雷伯菌噬菌体 JKP2,具有减少生物膜的潜力。
Virus Res. 2023 May;329:199107. doi: 10.1016/j.virusres.2023.199107. Epub 2023 Apr 2.
2
[Biological characteristics and genomic information of a bacteriophage against pan-drug resistant in a burn patient and its effects on bacterial biofilm].[烧伤患者中一株抗泛耐药菌噬菌体的生物学特性、基因组信息及其对细菌生物膜的影响]
Zhonghua Shao Shang Za Zhi. 2020 Jan 20;36(1):14-23. doi: 10.3760/cma.j.issn.1009-2587.2020.01.004.
3
Characterization of Novel Phage PG14 and Its Antibiofilm Efficacy.新型噬菌体 PG14 的特性及其抗生物膜功效。
Microbiol Spectr. 2022 Dec 21;10(6):e0199422. doi: 10.1128/spectrum.01994-22. Epub 2022 Nov 14.
4
Analysis of a new phage, KZag1, infecting biofilm of Klebsiella pneumoniae: genome sequence and characterization.分析一种新的噬菌体 KZag1 感染肺炎克雷伯氏菌生物膜的情况:基因组序列和特征。
BMC Microbiol. 2024 Jun 14;24(1):211. doi: 10.1186/s12866-024-03355-9.
5
Bacteriophage vB_kpnS-Kpn15: Unveiling its potential triumph against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae - Unraveling efficacy through innovative animal alternate models.噬菌体 vB_kpnS-Kpn15:揭示其针对产超广谱β-内酰胺酶的肺炎克雷伯菌的潜在胜利——通过创新的动物替代模型揭示疗效。
Microb Pathog. 2024 Oct;195:106891. doi: 10.1016/j.micpath.2024.106891. Epub 2024 Aug 28.
6
Isolation and genomic characterization of a novel Autographiviridae bacteriophage IME184 with lytic activity against Klebsiella pneumoniae.分离和基因组特征分析一种新型 Autographiviridae 噬菌体 IME184,其对肺炎克雷伯菌具有裂解活性。
Virus Res. 2022 Oct 2;319:198873. doi: 10.1016/j.virusres.2022.198873. Epub 2022 Jul 19.
7
Isolation, characterization, and genome analysis of bacteriophage P929 that could specifically lyase the KL19 capsular type of Klebsiella pneumoniae.分离、鉴定和基因组分析能特异性裂解肺炎克雷伯菌 KL19 荚膜型的噬菌体 P929。
Virus Res. 2022 Jun;314:198750. doi: 10.1016/j.virusres.2022.198750. Epub 2022 Mar 18.
8
Characterization and comprehensive genome analysis of novel bacteriophage, vB_Kpn_ZCKp20p, with lytic and anti-biofilm potential against clinical multidrug-resistant .新型噬菌体 vB_Kpn_ZCKp20p 的特性及全基因组分析,该噬菌体具有溶菌和抗临床多重耐药生物膜的潜力。
Front Cell Infect Microbiol. 2023 Jan 23;13:1077995. doi: 10.3389/fcimb.2023.1077995. eCollection 2023.
9
Characterization and genome analysis of Klebsiella phage P509, with lytic activity against clinical carbapenem-resistant Klebsiella pneumoniae of the KL64 capsular type.P509 噬菌体的特性与基因组分析,对 KL64 荚膜型碳青霉烯类耐药肺炎克雷伯菌具有溶菌活性。
Arch Virol. 2020 Dec;165(12):2799-2806. doi: 10.1007/s00705-020-04822-0. Epub 2020 Sep 28.
10
Characterization of Siphoviridae phage Z and studying its efficacy against multidrug-resistant Klebsiella pneumoniae planktonic cells and biofilm.长尾噬菌体科噬菌体Z的特性及其对多重耐药肺炎克雷伯菌浮游细胞和生物膜的作用研究
J Med Microbiol. 2015 Apr;64(Pt 4):454-462. doi: 10.1099/jmm.0.000040. Epub 2015 Feb 13.

引用本文的文献

1
Isolation and characterization of a novel phage targeting Klebsiella pneumoniae K2 capsular type.一种靶向肺炎克雷伯菌K2荚膜型的新型噬菌体的分离与鉴定。
Braz J Microbiol. 2025 Jun 6. doi: 10.1007/s42770-025-01707-9.
2
Analysis of a novel phage as a promising biological agent targeting multidrug resistant Klebsiella pneumoniae.一种新型噬菌体作为靶向多重耐药肺炎克雷伯菌的有前景生物制剂的分析
AMB Express. 2025 Mar 5;15(1):37. doi: 10.1186/s13568-025-01846-0.
3
Isolation, Characterization, and Anti-Biofilm Activity of a Novel Against K24 Capsular Type, Multidrug-Resistant Clinical Isolates.

本文引用的文献

1
Combination of pre-adapted bacteriophage therapy and antibiotics for treatment of fracture-related infection due to pandrug-resistant Klebsiella pneumoniae.噬菌体预先适应疗法联合抗生素治疗泛耐药肺炎克雷伯菌致骨折相关感染
Nat Commun. 2022 Jan 18;13(1):302. doi: 10.1038/s41467-021-27656-z.
2
Virulent Bacteriophage MSK, Morphological and Genome Resemblance With Rtp Bacteriophage Inhibits the Multidrug-Resistant Bacteria.烈性噬菌体MSK,与Rtp噬菌体在形态和基因组上的相似性可抑制多重耐药细菌。
Front Microbiol. 2021 Aug 24;12:706700. doi: 10.3389/fmicb.2021.706700. eCollection 2021.
3
Novel Drexlerviridae bacteriophage KMI8 with specific lytic activity against Klebsiella michiganensis and its biofilms.
一种新型[物质]对K24荚膜型多重耐药临床分离株的分离、表征及抗生物膜活性
Antibiotics (Basel). 2025 Feb 5;14(2):157. doi: 10.3390/antibiotics14020157.
4
Relationship between biofilm formation and antibiotic resistance of and updates on antibiofilm therapeutic strategies.生物膜形成与抗生素耐药性之间的关系以及抗生物膜治疗策略的最新进展。
Front Cell Infect Microbiol. 2024 Feb 23;14:1324895. doi: 10.3389/fcimb.2024.1324895. eCollection 2024.
新型 Drexlerviridae 噬菌体 KMI8 对密歇根克雷伯氏菌及其生物膜具有特定的溶菌活性。
PLoS One. 2021 Sep 7;16(9):e0257102. doi: 10.1371/journal.pone.0257102. eCollection 2021.
4
Biological Characterization and Evolution of Bacteriophage T7-△holin During the Serial Passage Process.噬菌体T7-△溶菌酶在连续传代过程中的生物学特性及进化
Front Microbiol. 2021 Aug 2;12:705310. doi: 10.3389/fmicb.2021.705310. eCollection 2021.
5
Basics for Improved Use of Phages for Therapy.改善噬菌体治疗应用的基础
Antibiotics (Basel). 2021 Jun 16;10(6):723. doi: 10.3390/antibiotics10060723.
6
Improving Phage-Biofilm In Vitro Experimentation.优化噬菌体-生物膜体外实验。
Viruses. 2021 Jun 19;13(6):1175. doi: 10.3390/v13061175.
7
Primed CRISPR-Cas Adaptation and Impaired Phage Adsorption in Streptococcus mutans.变形链球菌中 CRISPR-Cas 适应性的增强和噬菌体吸附的受损。
mSphere. 2021 May 19;6(3):e00185-21. doi: 10.1128/mSphere.00185-21.
8
Characterization of a lytic EBP bacteriophage with large size genome against Enterobacter cloacae.针对阴沟肠杆菌的裂解 EBP 噬菌体的大基因组特征。
APMIS. 2021 Aug;129(8):461-469. doi: 10.1111/apm.13138. Epub 2021 Jun 1.
9
Microtiter plate assays to assess antibiofilm activity against bacteria.微孔板法检测抗细菌生物膜活性。
Nat Protoc. 2021 May;16(5):2615-2632. doi: 10.1038/s41596-021-00515-3. Epub 2021 Apr 28.
10
Synergistic action of phage phiIPLA-RODI and lytic protein CHAPSH3b: a combination strategy to target Staphylococcus aureus biofilms.噬菌体phiIPLA - RODI与裂解蛋白CHAPSH3b的协同作用:一种靶向金黄色葡萄球菌生物膜的联合策略。
NPJ Biofilms Microbiomes. 2021 Apr 22;7(1):39. doi: 10.1038/s41522-021-00208-5.